BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chatterjee S, Ghosal S, Chatterjee S. Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. World J Diabetes 2016; 7(18): 441-448 [PMID: 27795818 DOI: 10.4239/wjd.v7.i18.441] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Ibnat N, Zaman R, Uddin MB, Chowdhury E, Lee CY. Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in rats. World J Diabetes 2022; 13(8): 613-621 [DOI: 10.4239/wjd.v13.i8.613] [Reference Citation Analysis]
2 Xiang T, Zhang S, Li Q, Li L, Liu H, Chen C, Yang G, Yang M. GPHB5 Is a Biomarker in Women With Metabolic Syndrome: Results From Cross-Sectional and Intervention Studies. Front Endocrinol (Lausanne) 2022;13:893142. [PMID: 35757403 DOI: 10.3389/fendo.2022.893142] [Reference Citation Analysis]
3 Bortolato A, Mason JS. Discovery of HTL26119. Contemporary Accounts in Drug Discovery and Development 2022. [DOI: 10.1002/9781119627784.ch9] [Reference Citation Analysis]
4 Rajput R, Ghosh S, Banerjee S, Bansal B, Chawla M, Ahluwalia AI, Lathia T, Das AK. First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context. Indian J Endocrinol Metab 2022;26:417-27. [PMID: 36618518 DOI: 10.4103/ijem.ijem_217_22] [Reference Citation Analysis]
5 Kramer HJ, Joshi S. Metabolic syndrome and kidney disease. Nutritional Management of Renal Disease 2022. [DOI: 10.1016/b978-0-12-818540-7.00028-8] [Reference Citation Analysis]
6 Ananthy V, Priyadharsini RP, Subramanian U. Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive Review. SBV Journal of Basic, Clinical and Applied Health Science 2021;4:39-45. [DOI: 10.5005/jp-journals-10082-03111] [Reference Citation Analysis]
7 Congreve M, Christopher JA, Graaf C. Structure‐Based Drug Design for G Protein‐Coupled Receptors. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc269] [Reference Citation Analysis]
8 Wang M, Yoon G, Song J, Jo J. Exendin-4 improves long-term potentiation and neuronal dendritic growth in vivo and in vitro obesity condition. Sci Rep 2021;11:8326. [PMID: 33859286 DOI: 10.1038/s41598-021-87809-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 McCarty MF, Lerner A. Perspective: Prospects for Nutraceutical Support of Intestinal Barrier Function. Adv Nutr 2021;12:316-24. [PMID: 33126251 DOI: 10.1093/advances/nmaa139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
10 Alhadeff R, Warshel A. A free-energy landscape for the glucagon-like peptide 1 receptor GLP1R. Proteins 2020;88:127-34. [PMID: 31294890 DOI: 10.1002/prot.25777] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Kalra S, Das AK, Sahay RK, Baruah MP, Tiwaskar M, Das S, Chatterjee S, Saboo B, Bantwal G, Bhattacharya S, Priya G, Chawla M, Brar K, Raza SA, Aamir AH, Shrestha D, Somasundaram N, Katulanda P, Afsana F, Selim S, Naseri MW, Latheef A, Sumanatilleke M. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Ther 2019;10:1645-717. [PMID: 31359367 DOI: 10.1007/s13300-019-0669-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
12 Onoviran OF, Li D, Toombs Smith S, Raji MA. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Ther Adv Chronic Dis 2019;10:2040622319862691. [PMID: 31321014 DOI: 10.1177/2040622319862691] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
13 Hamasaki H. Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment? World J Diabetes 2018; 9(8): 138-140 [PMID: 30147850 DOI: 10.4239/wjd.v9.i8.138] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
14 Wysham CH, Campos C, Kruger D. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications. Clin Diabetes 2018;36:149-59. [PMID: 29686454 DOI: 10.2337/cd17-0064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
15 Zhang L, Zhang S, Yin Y, Xing S, Li W, Fu X. Hypoglycemic effect and mechanism of isoquercitrin as an inhibitor of dipeptidyl peptidase-4 in type 2 diabetic mice. RSC Adv 2018;8:14967-74. [DOI: 10.1039/c8ra00675j] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
16 Jazayeri A, Rappas M, Brown AJH, Kean J, Errey JC, Robertson NJ, Fiez-Vandal C, Andrews SP, Congreve M, Bortolato A, Mason JS, Baig AH, Teobald I, Doré AS, Weir M, Cooke RM, Marshall FH. Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature 2017;546:254-8. [PMID: 28562585 DOI: 10.1038/nature22800] [Cited by in Crossref: 130] [Cited by in F6Publishing: 131] [Article Influence: 21.7] [Reference Citation Analysis]
17 Cho H, Um J, Lee JH, Kim WH, Kang WS, Kim SH, Ha HH, Kim YC, Ahn YK, Jung DW, Williams DR. ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes. Sci Rep 2017;7:44186. [PMID: 28272459 DOI: 10.1038/srep44186] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
18 Mietlicki-Baase EG, McGrath LE, Koch-Laskowski K, Krawczyk J, Pham T, Lhamo R, Reiner DJ, Hayes MR. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance. Physiol Behav 2017;173:9-14. [PMID: 28119159 DOI: 10.1016/j.physbeh.2017.01.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
19 Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, Sun X, Tong N. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:284-295. [PMID: 28065744 DOI: 10.1016/j.clinre.2016.11.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]